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Background: Fat tissue, and particularly visceral fat, is known to play a role in low grade sys-
temic inflammation in COPD, and is likely to contribute to the excess cardiovascular comorbidity
in COPD. Therefore, we aimed to study 18FDG-PET-assessed inflammation of the aorta and the
(visceral) fat, and evaluate its interrelations and differences in subjects with and without COPD.
Methods: We retrospectively identified 42 patients (71% male, 48% current smokers, mean age
66.6  8.3 years, mean BMI 25.1  4.3 kg/m2), who underwent 18F-FDG-PET/CT for suspected
early stage bronchus carcinoma. COPD-diagnosis was based on spirometry and defined as
FEV1/FVC < lower limit of normal. Inflammatory status of aortic and fat regions was defined
as the average of obtained maximum target-to-background ratios (meanTBRmax). The TBR is
the standardized uptake value (SUV) normalized to 18F-FDG blood pool activity.r of Expertise for Chronic Organ Failure, PO Box 4080, 6080 AB Haelen, Hornerheide 1, 6085 NM Horn,
644; fax: þ31 (0)475 587 592.
ciro-horn.nl (L.E.G.W. Vanfleteren).
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884 L.E.G.W. Vanfleteren et al.Results: Compared to controls, patients with COPD (nZ 19; 45%) had increased meanTBRmax of
both the abdominal aorta (1.31 0.14 vs. 1.49 0.31; pZ 0.02) and the abdominal visceral fat
(0.28  0.09 vs. 0.38  0.18; pZ 0.047), while inflammatory activity of the abdominal subcu-
taneous fat failed to show statistically significant differences (0.21  0.09 vs. 0.24  0.09;
pZ 0.345). In all patients, meanTBRmax of abdominal visceral fat was correlated with meanTBRmax
of the abdominal aorta, independently of age and BMI (bZ 0.590, pZ 0.002).
Conclusion: Metabolic activity of the abdominal aorta and visceral fat is increased in COPD pa-
tients compared to peers. The degree of visceral fat metabolic activity is associated with aortic
inflammation. More prospective research is warranted concerning the role of visceral fat in the
development of vascular comorbidity in COPD.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Although defined by the presence of chronic airflow limi-
tation, chronic obstructive pulmonary disease (COPD) is
nowadays considered a complex, heterogeneous and multi-
component condition [1,2]. It is increasingly recognized
that cardiovascular disease has an increased incidence in
subjects with COPD even when controlled for shared risk
factors as smoking [3,4]. In subjects with mild to moderate
COPD, the main cause of death is cardiac [5].
COPD is associated with low-grade systemic inflamma-
tion, which has been suggested to originate from the pul-
monary compartment and then again stimulate the
atherosclerotic process [6]. However, the COPD-specificity
of this low-grade systemic inflammation is still unclear
and a matter of debate [6,7]. Adipose tissue is known as a
metabolic active organ and important source of inflamma-
tory markers [8] and its role as a cardiovascular risk factor
has been well determined [9]. Also in COPD patients,
increased levels of systemic inflammation have been
particularly reported in obese subjects [7,10e12]. In addi-
tion, an independent cluster of COPD patients has been
recognized, characterized by a high proportion of obesity,
cardiovascular disorders, diabetes and systemic inflamma-
tion [13,14].
Moreover, the inflammatory capacity of abdominal
visceral fat is considerably greater in comparison with other
fat depots [15,16]. Interestingly, recently, increased
visceral fat mass has been reported in non-obese COPD
compared to a well matched control group [17].
Positron emission tomography with 18F-fluorodeox-
yglucose (FDG-PET) has emerged as a novel and sensitive
imaging technique to identify both atherosclerotic disease
activity [18,19] and metabolic activity of the visceral fat
[20]. Increased aortic inflammation as measured by FDG-
PET has already been seen in COPD patients compared to
non-COPD ex-smokers [21].
We hypothesized that subjects with COPD had increased
metabolic activity of the visceral fat compared to controls
and that this might be associated with increased athero-
sclerotic activity. Therefore, using FDG-PET, we aimed to
study: 1)whether or not themetabolic activity of the visceral
fat, the subcutaneous fat and the aorta is increased in pa-
tients with COPD compared to matched controls; 2) Whether
or not the metabolic activity of the visceral or subcutaneous
fat is associated with aortic inflammatory activity.Methods
Study population
From January 2006 to August 2008, 43 consecutive subjects
who underwent non-contrast FDG/PET-CT scanning for
suspected bronchus carcinoma without evidence for
lymphatic or distant metastasis were retrospectively iden-
tified. One patient was excluded because of lacking
spirometry. A total of 42 patients were included for anal-
ysis. These retrospective analyses are IRB exempt due to
the use of de-identified, pre-existing data.
Recorded demographics
Smoking status, patients’ cardiovascular medical history
and pharmacological cardiovascular treatment (listed in
Table 2) were registered in the digitalized hospital charts.
“Any cardiovascular comorbidity” was defined as at least
one of the listed cardiovascular comorbidities in the history
of an individual patient.
FDG/PET-CT
Image analysis of the vessels
Image analysis was performed on a dedicated commercially
available workstation (Extended Brilliance Workspace
V4.0.0.3206; Philips Medical Systems Inc.; Cleveland, Ohio).
One experienced reader (A. v. M.) analyzed all scans
(example in Fig. 1). Methodology for analysis and repro-
ducibility of the measurements has been previously re-
ported [22].
The FDG-uptake in different aortic regions was quantified
as the maximum arterial standardized uptake value (SUV)
(highest pixel activity within the region of interest). The SUV
is the decay-corrected tissue concentration of FDG in kBq/
ml, adjusted for the injected FDG dose and the body weight
of the patient. By averaging the maximum SUV values of all
arterial slices of the different vascular territories analyzed a
meanSUVmax value was derived for all arteries.
The arterial target-to-background ratio (TBR) was
calculated by normalizing the arterial SUV for blood pool
activity by dividing the SUV values in the arteries by the
average blood mean SUV estimated from the superior vena
Figure 1 Examples of SUV measurements in regions of interest of the abdominal subcutaneous and visceral fat (left image) and
the aortic wall (right image).
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interest (ROIs) in consecutive slices of the vein and aver-
aging the obtained mean SUV values. The TBR is a blood-
normalized arterial SUV, considered to be a reflection of
arterial FDG-uptake and reflective of underlying macro-
phage activity [23]. The arterial TBR values obtained were
then averaged in order to derive a meanTBRmax for the
different parts of the aorta.
Image analysis of the fat tissue
Fat tissue regions, defined as subcutaneous fat tissue in the
neck, in the presternal area and in the abdominal region as
well as pericardial and the visceral abdominal fat tissue
were identified based on pre-defined ranges of Hounsfield
units (HU) of 70 to 110 from CT images as previously
described [20]. ROIs in the abdominal region (both subcu-
taneous as well as visceral) were placed around the um-
bilical region (example in Fig. 1). After CT fusion with the
PET images, ROIs were placed on at least three consecutive
slices whenever possible and mean and maximal SUV values
across those slices were averaged. ROIs were placed away
from regions of fat tissue with focally or diffusely increased
FDG-uptake, which are usually considered to reflect brown
fat tissue. In general, ROIs were not placed if an overspill
could not be excluded to the highest possible degree. As for
the vascular SUV values, fat tissue SUVs were corrected by
the blood pool activity of the superior vena cava in order to
obtain fat tissue TBR values, which we assume to reflect the
true metabolic activity and/or the inflamed state of fat
tissue cells.
Lung function and definition of COPD
Standardized spirometry (forced expiratory volume in the
first second [FEV1] and forced vital capacity [FVC]) was
performed in all subjects at the lung function laboratory of
MUMCþ (MasterScreen Body, Carefusion, Germany). Pa-
tients were stratified into the presence or absence of COPD
based on the modified global initiative for obstructive lung
disease initiative (GOLD) [24] criteria, being the lower limit
of normal (95th percentile) according to NHANES reference
equations [25]. Static lung volumes (total lung capacity[TLC], intra-thoracic gas volume [ITGV] and residual volume
[RV]) and carbon monoxide transfer factor (DLCO)(single
breath hold method) were determined in all patients
(MasterScreen Body, Carefusion, Germany).
Body composition analyses
All body height and weight measurements were derived
from the pulmonary function records. In the pulmonary
function laboratory these measurements have been stan-
dardized. Body mass index (BMI) was calculated as body
weight/height [2].
Statistics
All statistics were performed using Statistical Package for
the Social Sciences (SPSS) version 17.0. Results are
expressed as mean  standard deviation. After confirming
normal distribution of the data, independent samples Stu-
dent’s t-test was used to investigate differences in out-
comes between patients with and without COPD. To
investigate associations, simple and multivariate linear
regression was used with enter method.
Results
Patient characteristics
Characteristics of all patients are shown in Table 1. On
average they were elderly subjects, with a normal BMI, a
pulmonary function with mildly impaired FEV1 and signs of
mild hyperinflation. Almost all subjects had a history of
smoking; half of them quitted smoking previously. Two
thirds had a history of cardiovascular disease, 38% of the
patients used statins. Further information on cardiovascu-
lar comorbidity and medication use is shown in Table 2.
Stratified for the presence or absence of COPD, both
groups were well matched in terms of age, BMI, history of
smoking, known history of cardiovascular disease and use of
medications. Based on the inclusion criteria, subjects with
COPD had a worse pulmonary function with lower FEV1,
higher static lung volumes and lower diffusion capacity.
Table 1 Baseline characteristics.
All
n Z 42
No COPD
n Z 23
COPD
n Z 19
p
Demographics
Male 30 (71,4) 15 (65.2) 15 (78.9) 0.495
Age, years 66.6  8.3 65.2  8.3 68.4  8.3 0.226
BMI, kg/m2 25.1  4.3 26.2  4.3 23.7  4.0 0.058
Current smoker 20 (47.6) 10 (43.5) 10 (52.6) 0.647
Ex smoker 20 (47.6) 11 (47.8) 9 (47.4) 0.867
Never smoker 2 (4.8) 2 (8.7) 0 (0) 0.178
Pulmonary function
FEV1, liter 2.12  0.76 2.49  0.68 1.67  0.60 <0.001
FEV1, % predicted 81.4  26.5 97.7  22.5 61.7  15.5 <0.001
FVC, liter 3.29  0.82 3.36  0.88 3.21  0.75 0.569
FVC, % predicted 100.7  19.1 106.2  21.6 93.9  13.3 0.037
FEV1/FVC, % 62.5  13.3 72.4  5.3 50.5  9.5 <0.001
TLC, % predicted 107.7  17.1 102.3  14.3 113.8  18.4 0.049
ITGV, % predicted 124.5  33.2 107.7  18.3 143.4  26.4 0.002
RV, % predicted 135.8  45.0 113.5  26.6 160.9  48.8 0.002
TLCO, % predicted 67.6  22.2 75.5  20.2 57.9  21.1 0.011
Summary variables are presented as mean  standard deviation for quantitative variables, and count (percentage) for discrete vari-
ables. BMI: Body Mass Index; FEV1: Forced expiratory volume in the first second; FVC: Forced vital capacity; TLC: total lung capacity;
ITGV: intra-thoracic gas volume; RV: residual volume; TLCO: Transfer factor for carbon monoxide.
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COPD
The meanTBRmax of the abdominal aorta was significantly
increased in subjects with COPD compared to their peers.
meanTBRmax of all other aortic segments analyzed and,
consequently, of the whole aorta were not statistically
different between the two groups (Table 3). After adjust-
ment for age, gender, BMI and current smoking; the presence
of COPD (Beta: 0.341; T-test: 2.05; p Z 0.048) was still an
independent predictor of abdominal aortic meanTBRmax.
Fat tissue activity in subjects with and without
COPD
In three patients abdominal fat could not be scored
because of the absence of measurable fat or because of
technical reasons. In subjects with successful measure-
ment, the meanTBRmax of the abdominal visceral fat was
increased in subjects with COPD compared to the non-COPD
controls. Furthermore, the meanTBRmax of the thoracic
visceral fat tended to be higher in patients with COPD
reaching close to statistical significance. This was also due
for the meanTBRmax of the subcutaneous fat regions, which
tended to be higher in patients with COPD. However, these
differences failed to be statistically significant (Table 3).
After adjusting for age, gender, BMI and current smoking,
the association between the presence of COPD and mean-
TBRmax of the abdominal visceral fat disappeared (Beta:
0.54; T-test: 0.33; p Z 0.741).
Fat tissue activity and aortic inflammation
In both simple and multivariate linear regression model,
adjusting for BMI, age, gender and current smoking status,meanTBRmax of both abdominal and thoracic visceral fat
predicted the meanTBRmax of the whole aorta. Regarding
subcutaneous fat, the thoracic region, but not the
abdominal region was associated with the meanTBRmax of the
whole aorta (Table 4).
Subcutaneous versus visceral fat
In simple linear regression, meanTBRmax of visceral and
abdominal subcutaneous fat are positively correlated for
both the abdominal (b Z 0.590, t-test Z 3.442,
p Z 0.002) and thoracic (b Z 0.481, t-test Z 3.336,
pZ 0.002) compartments. In addition, for both abdominal
and thoracic sites, meanTBRmax of the visceral fat was
significantly higher compared to subcutaneous fat
(abdominal compartment: 0.33  0.14 versus 0.22  0.09
respectively, p < 0.001; thoracic compartment:
0.36  0.13 versus 0.23  0.09 respectively, p < 0.001).
This finding was independent from the presence or
absence of COPD.
Discussion
Using FDG-PET, this study showed increased inflammatory
activity of the abdominal aorta in subjects with COPD,
compared to subjects without COPD, even when adjusted
for gender, age, BMI and current smoking. In addition,
increased metabolic activity of the abdominal visceral fat
was seen in subjects with COPD compared to subjects
without COPD, although not independent from gender,
age, BMI and current smoking. Metabolic activity of the
different subcutaneous fat compartments was compara-
ble in both groups. Although visceral fat was significantly
more metabolic active, compared to subcutaneous fat,
the metabolic activity of both visceral and subcutaneous
Table 2 Reported cardiovascular comorbidity and medication use.
All
n Z 42
No COPD
n Z 23
COPD
n Z 19
p
Cardiovascular comorbidity
Myocardial infarction 8 (19.0) 2 (8.7) 6 (31.6) 0.06
Cerebrovascular disease 6 (14.3) 4 (17.4) 2 (10.5) 0.527
Chronic heart failure 0 (0) 0 (0) 0 (0) e
Peripheral arterial disease 6 (14.3) 4 (17.4) 2 (10.5) 0.527
Operated abdominal aneurysm 2 (4.8) 0 (0) 2 (10.5) 0.111
Invasively treated coronary disease 7 (16.7) 4 (17.4) 3 (15.8) 0.89
Angina pectoris 4 (9.5) 2 (8.7) 2 (10.5) 0.841
Treated hypertension 16 (38.1) 9 (39.1) 7 (36.8) 0.879
Arrhythmia 4 (9.5) 1 (4.3) 3 (15.8) 0.209
Any cardiovascular comorbidity 28 (66.7) 16 (69.6) 12 (63.2) 0.661
Diabetes mellitus 5 (11.9) 4 (17.4) 1 (5.3) 0.227
Cardiovascular medication
Any cardiovascular medication 29 (69.0) 17 (73.9) 12 (63.2) 0.453
Statines 16 (38.1) 9 (39.1) 7 (36.8) 0.879
ACE inhibitor or ARB 12 (28.6) 7 (30.4) 5 (26.3) 0.769
Beta blocker 16 (38.1) 10 (43.5) 6 (31.6) 0.429
Calcium antagonist 6 (14.3) 2 (8.7) 4 (21.1) 0.255
Diuretics 5 (11.9) 5 (21.7) 0 (0) 0.03
Nitrates 8 (19.0) 3 (13.0) 5 (26.3) 0.276
Antiarrythmics 2 (4.8) 0 (0.0) 2 (10.5) 0.111
Digitalis 2 (4.8) 1 (4.3) 1 (5.3) 0.89
Platelet aggregation inhibitor 16 (38.1) 10 (43.5) 6 (31.6) 0.429
Coumarins 3 (7.1) 2 (8.7) 1 (5.3) 0.667
ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker.
A retrospective 18F-FDG-PET/CT pilot study 887fat predicted the inflammatory activity of the aorta in all
subjects, independent of gender, age, BMI and smoking.
Vascular inflammation can nowadays sensitively be
detected by FDG-PET. FDG reflects the metabolic rate of
glucose, a process known to be enhanced in inflamed tis-
sue. Vascular FDG uptake has been shown to be significantly
associated with both the degree of macrophage infiltration
and the levels of inflammatory gene expression in athero-
sclerotic plaque [27e29]. Likewise, FDG-PET can also non-
invasively image the metabolic activity in visceral and
subcutaneous fat tissue and might therefore serve as a
surrogate marker of fat tissue inflammation [20,30].
The metabolic processes in the abdominal fat, and
particular in visceral fat reflect the secretion of adipokines
and macrophage infiltration and activation [31]. These
processes are known to have a key role in the atheroscle-
rotic process as they induce endothelial dysfunction both
directly through proinflammatory and prothrombotic fac-
tors and indirectly through insulin resistance and oxidative
stress [31]. The present study corroborates the possible role
of metabolic activity of fat tissue, in particular visceral fat,
in the atherosclerotic process. Indeed, visceral fat meta-
bolic activity is more strongly associated with aortic
inflammation, compared to subcutaneous fat. Visceral fat
also demonstrated an increased FDG-uptake compared to
the subcutaneous fat, which is consistent with earlier re-
ports [15,16]. Previously, also macrophages have been
found more frequently in visceral compared with subcu-
taneous adipose tissue [32]. Obesity and the metabolic
syndrome have been revealed as the most important risk
factors for increased vascular FDG uptake [22,33,34].However, to the best of our knowledge, so far no study
demonstrated the association of FDG-PET measured meta-
bolic activity of fat tissue and atherosclerotic activity, in
general or in subjects with and without COPD.
It was previously shown that COPD patients exhibited
aortic inflammation as measured by FDG-PET that fell be-
tween the aortic inflammation exhibited by ex-smokers and
that by metabolic syndrome patients [21]. Here, we confirm
that subjects with COPD have increased inflammatory ac-
tivity of the abdominal aorta compared to non-COPD sub-
jects, even when adjusted for gender, age, BMI and current
smoking. These findings are in line with the wealth of data
indicating the increased cardiovascular risk in subjects with
COPD, even when shared cardiovascular risk factors are
taken into account [3,4,35e37].
Although not independent from gender, age, BMI and
current smoking, this study suggested increased metabolic
activity of the visceral fat in subjects with COPD compared
to non-COPD peers. Given the high and independent asso-
ciation between the metabolic activity of the visceral fat
and the inflammatory activity of the aorta, this study em-
phasizes the possible involvement of visceral fat in an
enhanced atherosclerotic process in COPD and conse-
quently excess cardiovascular comorbidity. This is further
corroborated by recent studies reporting increased visceral
fat (independent of total fat mass) in subjects with COPD in
matched cohorts [17,38]. Furthermore a contribution of
visceral fat to inflammatory pathways was demonstrated,
which was associated with mortality in older persons with
obstructive lung disease [17]. Interestingly, visceral fat
accumulation has also been reported in other chronic
Table 3 Maximal target to background ratio for different fat compartments and aortic regions in subjects with and without
COPD.
meanTBRmax
No COPD n Z 23
meanTBRmax
COPD n Z 19
p
Ascending aorta 1.40  0.13 1.44  0.32 0.619
Aortic arch 1.39  0.15 1.46  0.38 0.429
Descending aorta 1.38  0.1 1.51  0.47 0.224
Abdominal aorta 1.31  0.14 1.49  0.31 0.019
Whole aorta 1.40  0.13 1.44  0.32 0.619
meanTBRmax
No COPD n Z 21
meanTBRmax
COPD n Z 18
p
Abdominal subcutaneous fat 0.21  0.09 0.24  0.09 0.345
Abdominal visceral fat 0.28  0.09 0.38  0.18 0.047
Thoracic subcutaneous fat 0.21  0.07 0.25  0.12 0.239
Thoracic visceral fat 0.32  0.11 0.4  0.15 0.061
Neck subcutaneous fat 0.20  0.09 0.29  0.19 0.063
Table 4 Uni- and multivariate (including BMI and age) linear regression between meanTBRmax of the whole aorta and mean-
TBRmax of the different fat compartments.
meanTBRmax of the whole aorta as
the dependent variable
Univariate linear
regression
Multivariate linear regression (adjusting for
BMI, age, gender and current smoking status)
Beta t-test p-Value Beta t-test p-Value
meanTBRmax, thoracic subcutaneous fat 0.553 4.095 <0.001 0.592 3.933 <0.001
meanTBRmax, thoracic visceral fat 0.667 5.439 <0.001 0.788 5.890 <0.001
meanTBRmax, abdominal subcutaneous fat 0.336 2.168 0.037 0.362 1.822 0.078
meanTBRmax, abdominal visceral fat 0.610 4.687 <0.001 0.854 5.960 <0.001
888 L.E.G.W. Vanfleteren et al.diseases associated with low-grade systemic inflammation,
including rheumatoid arthritis [39], Crohn’s disease [40],
and psoriasis [41]. It would be interesting to investigate
whether or not visceral fat in these conditions is not only
excessive but also metabolic more active and related to
atherosclerotic activity.
This study has several limitations. First this is a retro-
spective analysis with a non-vascular tailored FDG-PET
protocol. Second, this study probably lacked power to see
differences in all aortic regions and fat compartments. In
spite of this, subjects were well matched and we were able
to demonstrate significant differences. Third, in general
and in this study there is lack of histological confirmation of
the correlation between inflammation in fat tissue and
increased FDG uptake. A fourth limitation is the lack of
systemic inflammatory markers and serum cholesterol
levels in this study. Finally, subjects underwent FDG-PET
for suspected lung cancer, which might influence the re-
sults. However, we included only subjects without evidence
for lymphatic of distant metastasis. In addition, probably
due to this population, subjects were well matched for
history of smoking.
In conclusion, we were able to show that subjects with
COPD have increased inflammatory activity of the aortic
wall and increased metabolic activity of the abdominal
visceral fat compared to non-COPD subjects. In addition,
the degree of FDG uptake in the visceral and subcutaneous
fat independently predicted the inflammation of the aortic
wall. Finally, visceral fat was metabolically more activethan subcutaneous fat as revealed by FDG-PET. These
findings shed new light on the origin of increased vascular
risk in subjects with COPD and emphasize the possible role
of visceral fat in the atherosclerotic process in COPD and
warrant further prospective and well-powered trials.Authorship and contributorship
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